FIDELITY & GUARANTY LIFE INSURANCE CO sold $2.7M of CCAP

FIDELITY & GUARANTY LIFE INSURANCE CO sold 265,490 shares of Crescent Capital BDC, Inc. (CCAP) at an average of $10.28 ($10.23–$10.33, $2.73M total) across 2 trades over 2026-09-08 to 2026-09-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · FIDELITY & GUARANTY LIFE INSURANCE CO
Published Sep 9, 2026, 10:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 10:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CCAP
Neutral
high confidence
Mentioned
$CCAP
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CCAPNeutralLow
01

Why it matters

The disclosed sale provides transparency but is unlikely to affect CCAP's stock price materially.

02

Market read

Primary insider sale disclosure; modest size limits trading relevance.

03

What to watch

Potential upcoming capital calls or portfolio rebalancing by the insurer could drive the sale, not company performance.

Relevance 5/10Novelty 8/10Timing: filing today (2026‑09‑09)

Background

Form 4 filings disclose insider transactions; a 10% owner selling shares via a pre‑arranged plan is standard reporting.

Company-level read

Ticker impact

$CCAPNeutralHigh confidence
Context

Fidelity & Guaranty Life Insurance Co sold 265,490 shares of Crescent Capital BDC, Inc. for $2.73M via a 10b5‑1 plan, filed on 2026‑09‑09.

Expected impact

Minor downward pressure, unlikely to move price materially.

Evidence & confidence

Form 4 disclosures are primary source; the transaction size is small for a BDC, and the sale is pre‑arranged, suggesting no new information about company fundamentals.

Market effects

Insider sales in BDCs are monitored but this modest sale does not signal sector‑wide trends.

US market only; no broader regional effect.

Limited to investors tracking CCAP.

Counterpoint

The sale could be interpreted as a lack of confidence, but 10b5‑1 plans are routine and may not reflect sentiment.

Key entities

  • Crescent Capital BDC, Inc.

    US‑listed business development company (ticker CCAP).

  • Fidelity & Guaranty Life Insurance Co

    10% owner of CCAP filing the Form 4.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CCAPHigh

Crescent Capital Q3 2026 slides: earnings beat, $50M buyback unveiled

Crescent Capital BDC (CCAP) reported Q3 2026 earnings of $0.37 per share, beating estimates. The company announced a $50M share buyback and a joint venture to reduce leverage. Shares rose 6.82% in after-hours trading to $9.87, still below NAV. Portfolio assets reached $1.6B, with 91% in senior secured positions. Net investment income declined year-over-year, and NAV per share fell 8%.

$CCAPMed

Crescent Capital BDC, Inc. Reports Third Quarter 2026 Earnings Results

Crescent Capital BDC, Inc. (CCAP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Crescent Capital BDC, Inc. Reports Third Quarter 2026 Earnings Results; Declares a Fourth Quarter Base Dividend of $0.34 Per Share and Announces a $50 Million Share Repurchase Program LOS ANGELES, November 9, 2026 — Crescent Capital BDC, Inc. (“Crescent BDC” or “Company”) (NASDAQ

$CCAPMed

Crescent Capital BDC, Inc. Reports Second Quarter 2026 Earnings Results

Crescent Capital BDC, Inc. (CCAP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Crescent Capital BDC, Inc. Reports Second Quarter 2026 Earnings Results; Declares a Third Quarter Base Dividend of $0.34 Per Share LOS ANGELES, August 10, 2026 — Crescent Capital BDC, Inc. (“Crescent BDC” or “Company”) (NASDAQ: CCAP) today reported net investment income of $0.36